Aroa Biosurgery reports low infection rates in 411-patient Myriad soft tissue reconstruction study
Reuters2026/09/07 00:47- Aroa Biosurgery announced peer-reviewed interim results from its ongoing MASTRR Registry evaluating Myriad in complex soft-tissue reconstruction.
- Results were published in Advances in Therapy, marking the latest disclosure from the registry rather than a future conference presentation.
- The analysis reported a favorable safety profile, with low infection rates in a high-risk, real-world inpatient population.
- No adverse events were deemed definitely related to Myriad products, supporting the device’s clinical positioning versus competing bioscaffolds.
- The company cited strong commercial momentum, including 54% sales growth in FY26, as the evidence base expands.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
